Skip to main content
Back to News & Events

Analysis Group HEOR Consultants to Present at ISPOR Europe 2025

Event: ISPOR Europe 2025 Dates: 9–12 November 2025 Host: ISPOR – The International Society for Pharmacoeconomics and Outcomes Research Location: Glasgow, Scotland

Analysis Group, a global leader in health economics and outcomes research (HEOR), will present an educational symposium and 11 research posters at ISPOR Europe 2025, which will be hosted at the Scottish Event Campus in Glasgow, Scotland.

Managing Principal Eric WuPrincipal Jimmy Royer, Vice President Rajeev Ayyagari, and Dr. Frank Hu (Harvard T.H. Chan School of Public Health) will present an educational symposium titled “Generative AI: Driving the Next Era of Evidence-Based Medicine.” The symposium will explore the frontiers of GenAI, highlight key developments and challenges, and showcase its applications in HEOR and RWE. It will also introduce a new RWE research initiative jointly launched by Harvard T.H. Chan School of Public Health and Analysis Group to advance precision health and apply AI to deepen our understanding of disease and treatment outcomes.   

Further details on the symposium and posters are available in our ISPOR 2025 Presentation Guide and on ISPOR’s website.

Associated People

Jimmy Royer

Jimmy Royer

Principal

Dr. Royer applies a broad range of quantitative tools to address client needs in data science, statistics, HEOR, finance, intellectual property, competition policy, and antitrust cases in the United States, Canada, and the EU. His recent work includes predicting the potential future onset of rare or undiagnosed conditions with machine learning models; predicting whether patents would be considered essential to technological standards if challenged in courts; valuing patents in the communications industry; evaluating damages related to product defects; analyzing investment guidelines in securities lending suits; addressing allegations of monopolization in major antitrust cases involving high tech firms; and supporting many academic experts on mutual fund market timing and excess fee cases. In addition, Dr. Royer has conducted extensive academic research and coauthored books and papers on topics such as using new AI advances in HEOR; predicting treatment resistance in tuberculosis, using machine learning algorithms in propensity score models; measuring the impact of ESO backdating on shareholders’ wealth; analyzing mutual fund pricing; analyzing antitrust limit pricing; valuing private investments for hospitals in Canada; determining the impact of hypertension therapies on mortality; and comparing unemployment compensation in different countries.

View Bio
View All Consultants